Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 3, 2003, Pages 1024-1036

  Samochocki, Marek ^a   Höffle, Anja ^a   Fehrenbacher, Andreas ^a   Jostock, Ruth ^a   Ludwig, Jürgen ^a   Christner, Claudia ^a   Radina, Martin ^a   Zerlin, Marion ^a   Ullmer, Christoph ^b   Pereira, Edna F R ^c   Lübbert, Hermann ^b   Albuquerque, Edson X ^d   Maelicke, Alfred ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Biofrontera Pharmaceuticals GmbH   (Germany)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERICALLY POTENTIATING LIGAND; CHOLINERGIC RECEPTOR; DICHLORFOS; DONEPEZIL; GALANTAMINE; LIGAND; METRIFONATE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

ALLOSTERIC REGULATION; ANIMALS; CARBAMATES; CELLS, CULTURED; CHOLINESTERASE INHIBITORS; GALANTAMINE; HUMANS; INDANS; MICE; NEURONS; PHENYLCARBAMATES; PIPERIDINES; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; RECOMBINANT FUSION PROTEINS; TACRINE; TRICHLORFON;

EID: 10744232323     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.045773     Document Type: Article

References (38)

1. Albuquerque EX, Pereira EFR, Alkondon M, Schrattenholz A, and Maelicke A (1997) Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. J Recept Signal Transduct Res 17:243-266.
2. Alkondon M, Rocha ES, Maelicke A, and Albuquerque EX (1996) Diversity of nicotinic acetylcholine receptors in rat brain. α-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release. J Pharmacol Exp Ther 278:1460-1471.
3. Biekel U, Thomsen T, and Weber W (1991) Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 50:420-428.
4. Buisson B, Gopalakrishnan M, Arneric SP, Sullivan JP, and Bertrand D (1996) Human α4β2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J Neurosci 16:7880-7891.
5. Burghaus L, Schultz U, and Krempel U (2000) Quantitative assessment of nicotinic acetylcholine receptors proteins in the cerebral cortex of Alzheimer's patients. Mol Brain Res 76:385-388.
6. Conti-Tronconi B, Diethelm BM, Wu X, Tang F, Bertazzon T, Schröder B, Reinhardt-Maelicke S, and Maelicke A (1991) α-Bungarotoxin and the competing antibody WF6 interact with different amino acids within the same cholinergic subsite. Biochemistry 30:2575-2584.
7. Court JA and Perry EK (1995) Distribution of nicotinic receptors in the CNS, in CNS Neurotransmitters and Neuromodulators (Stone TW ed) pp 85-104, CRC Press, London.
8. Doody RS (1999) Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol 9:69-77.
9. Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, and Bertrand D (1993) Chimaeric nicotinic-serotoninergic receptor combines distinct ligand binding and channel specificities. Nature (Lond) 366:479-483.
10. Ferris SH and Kluger A (1997) Assessing cognition in Alzheimer disease research. Alzheimer Dis Assoc Disord 11:45-49.
11. Giacobini E (2000) Cholinesterase inhibitors: from the calabar bean to Alzheimer therapy, in Cholinesterases and Cholinesterase Inhibitors (Giacobini E ed) pp 181-226, Martin Dunitz, London.
12. Gopalakrishnan M, Buisson B, Touma E, Giordano T, Campbell JE, Hu IC, Donnelly-Roberts D, Arneric SP, Bertrand D, and Sullivan JP (1995) Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur J Pharmacol 290:237-246.
13. 3H]-quinuclidinyl benzilate binding to muscarinic receptors in rat brain membranes with acetylcholinesterase inhibitors. Naunyn-Schmiedeberg's Arch Pharmacol 363:429-438.
14. Maelicke A and Albuquerque EX (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165-170.
15. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, and Zerlin M (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's Disease. Biol Psychiatry 49:279-288.
16. Maelicke A, Schrattenholz A, and Schröder H (1995) Modulatory control by noncompetitive agonists of nicotinic cholinergic neurotransmission in the central nervous system. Semin Neurosci 7:103-114.
17. Martin-Ruiz CM, Court JA, and Molnar E (1999) α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimers' disease. J Neurochem 73:1635-1640.
18. Okonjo KO, Kuhlmann J, and Maelicke A (1991) A second pathway of activation of the Torpedo acetylcholine receptor channel. Eur J Biochem 200:671-677.
19. Pereira EFR, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, and Albuquerque EX (1994) Physostigmine and galanthamine: probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270:768-778.
20. Pereira EFR, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, and Albuquerque EX (1993) Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 265:1474-1491.
21. Prinz H and Maelicke A (1992) Ligand binding to the membrane-bound acetylcholine receptor from Torpedo marmorate: a complete mathematical analysis. Biochemistry 31:6728-6738.
22. Raskind MA, Peskind ER, Wessel T, and Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261-2268.
23. Samochocki M, Zerlin M, Jostock R, Kormelink PJG, Luyten WHML, Albuquerque EX, and Maelicke A (2000) Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR. Acta Neurol Scand 176:68-73.
24. Santos MD, Alkondon M, Pereira EFR, Aracava Y, Eisenberg HM, Maelicke A, and Albuquerque EX (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
25. Schrattenholz A, Godovac-Zimmermann J, Schäfer HJ, and Maelicke A (1993) Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine. Eur J Biochem 216:671-677.
26. Schrattenholz A, Pereira EFR, Methfessel C, Roth U, Weber KH, Albuquerque EX, and Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
27. Schröder H, Giacobini E, Struble RG, Luitgen PGM, van der Zee EA, Zilles K, and Strosberg AD (1991) Muscarinic cholinoreceptive neurons in the frontal cortex in Alzheimer's disease. Brain Res Bull 27:631-636.
28. Schröder B, Reinhardt-Maelicke S, Schrattenholz A, McLane KE, Kretschmer A, Conti-Tronconi BM, and Maelicke A (1993) Monoclonal antibodies FK1 and WF6 define two neighbouring ligand binding sites on Torpedo acetylcholine receptors α-polypeptide. J Biol Chem 269:10407-10416.
29. Spencer CM and Noble S (1998) Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 13:391-410.
30. Stetzer E, Ebbinghaus U, Storch A, Poteur L, Schrattenholz A, Kramer G, Methfessel C, and Maelicke A (1996) Stable expression in HEK-293 cells of the rat α3/β4 subtype of neuronal nicotinic acetylcholine receptor. FEBS Lett 397:39-44.
31. Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, Weber KH, Reinhardt S, Lobron C, Hermsen B, Soskic V, et al. (1995) Physostigmine, galanthamine and codeine act as noncompetitive nicotinic agonists on clonal rat pheochromocytoma cells. Eur J Pharmacol 290:207-219.
32. Thomsen T, Kaden B, and Fischer JP (1991) Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 29:487-492.
33. Thomson T, Kewitz H, Bickel V, Straschill M, and Holl G (1991) Preclinical and clinical studies with galantamine, in Cholinergic Basis of Alzheimer's Disease (Becker R and Giacobini E eds), pp 328-336, Birhauser, Boston.
34. Wevers A, Monteggia L, Nowacki S, Bloch W, Schütz U, Lindstrom J, Pereira ER, Eisenberg H, Giacobini E, de Vos RA, et al. (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11:2551-2565.
35. Wilcock GK, Lilienfeld S, and Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 321:1445-1449.
36. Woodruff-Pak DS, Vogel RW, and Wenk GL (2001) Galantamine; effect on nicotinic receptor binding, acetylcholinesterase inhibition and learning. Proc Natl Acad Sci USA 98:2089-2094.
37. Zwart R and Vijverberg HPM (1997) Potentiation and inhibition of neuronal nicotinic receptors by atropin: competitive and noncompetitive effects. Mol Pharmacol 52:886-895.
38. Zwart R, van Kleef RG, Gotti C, Smulders CJ, and Vijverberg HP (2000) Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs. J Neurochem 75:2492-2500.